RIBOGENE ACQUISITION OF DARBY ASSETS FOR $4.4 MIL.
Executive Summary
RIBOGENE ACQUISITION OF DARBY ASSETS FOR $4.4 MIL. gives the small-molecule start-up company three products in its targeted therapeutic areas of oncology and HIV infection, the Hayward, Calif. biotech firm announced Jan. 6. RiboGene will buy Darby Pharmaceuticals' assets for $4.4 mil. to be paid over four years and warrants to purchase shares of RiboGene stock.